Reagentia en instrumenten voor immunologie, celbiologie en moleculaire biologie.
 
> (+)-Isomenthone [1196-31-2]

(+)-Isomenthone [1196-31-2]

Afdrukken Afdrukken
Log in alstublieft

Referentie HY-N7259-25mg

Formaat : 25mg

Merk : MedChemExpress


Description

(+)-Isomenthone is an enantiomer form of Menthone (HY-N2381). (+)-Isomenthone blocks TNF-α-triggered activation of the JNK and p38 MAPK pathways.(+)-Isomenthone inhibits TNF-α-mediated reductions in cell viability, increases in apoptosis, and downstream apoptotic events linked to pathway activation.(+)-Isomenthone protects human dermal fibroblasts against TNF-α-induced cell death under serum-deprived conditions[1].

In Vitro

(+)-Isomenthone (1-50 μM; 1-6 days) protects human dermal fibroblasts from TNF-α-induced cell death in a concentration- and time-dependent manner[1].
(+)-Isomenthone (50 μM; 6 days) significantly reduces TNF-α-induced apoptosis in human dermal fibroblasts, lowering the apoptotic cell population from 64% to 23% after 6 days of treatment[1].
(+)-Isomenthone (50 μM; 6 days) suppresses downstream apoptotic events in TNF-α-treated human dermal fibroblasts, including cytochrome c release, caspase-3 activation, and PARP cleavage, after 6 days of treatment[1].
(+)-Isomenthone (10-50 μM; 14h) does not modulate NF-κB activity in human dermal fibroblasts, either alone or in the presence of TNF-α[1].
(+)-Isomenthone (1-50 μM; 2h pretreatment, followed by TNF-α stimulation for 5-40min) inhibits TNF-α-induced phosphorylation of JNK and p38 MAPK (but not ERK) in human dermal fibroblasts, with significant suppression observed at 5, 10, 20, and 40 minutes after TNF-α stimulation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(+)-Isomenthone Related Antibodies

Cell Viability Assay[1]

Cell Line: human dermal fibroblasts (neonatal foreskin-derived)
Concentration: 1 μM (6 days); 10 μM (6 days); 50 μM (1-6 days)
Incubation Time: 1-6 days
Result: Inhibited TNF-α-induced cytotoxicity in a concentration- and time-dependent manner.
Increased cell viability to 92% relative to the TNF-α-treated group at day 6 with 50 μM.
Showed significant improvements in cell viability at all tested concentrations compared to TNF-α-only controls at day 6.
Maintained higher cell viability than the TNF-α-only group from day 3 onward with 50 μM, with statistically significant differences at days 3, 4, 5, and 6.

Apoptosis Analysis[1]

Cell Line: human dermal fibroblasts
Concentration: 50 μM
Incubation Time: 6 days
Result: Reduced the apoptotic cell population from 64% (TNF-α-only) to 23%, a statistically significant decrease.\nReduced the TUNEL-positive apoptotic cell population from 41% (TNF-α-only) to 8.3%, a statistically significant decrease.
Masse moléculaire

154.25

Formule

C10H18O
CAS No.
Appearance

Liquid (Density: 0.881±0.06 g/cm3)

Color

Colorless to light yellow

SMILES

O=C1[C@@H](C(C)C)CC[C@@H](C)C1
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvant et solubilité
In Vitro: 

DMSO : ≥ 100 mg/mL (648.30 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.4830 mL 32.4149 mL 64.8298 mL
5 mM 1.2966 mL 6.4830 mL 12.9660 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (16.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (16.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références